Sitting en banc, we unanimously set forth the law of divided infringement under 35 U.S.C. § (a). We con- clude that, in this case, substantial. Divided Infringement Since Akamai En Banc: Development of the Law. Following a lengthy trip to the U.S. Supreme Court and back, in August , the Akamai. In August of , the federal circuit met en banc in Akamai v. Limelight to settle a long-standing issue: When multiple parties perform all the.

Author: Vor Fenrisida
Country: Jamaica
Language: English (Spanish)
Genre: Literature
Published (Last): 28 September 2007
Pages: 412
PDF File Size: 1.83 Mb
ePub File Size: 10.82 Mb
ISBN: 919-8-83360-162-8
Downloads: 78121
Price: Free* [*Free Regsitration Required]
Uploader: Mezizahn

Food and Drug Administration issues, including citizen petitions, Orange Book listing, and trademark issues. The court said that the jury had heard substantial evidence from which it could find that Limelight directed or controlled its customers’ performance of each remaining method step that Limelight did not itself perform. He also counsels on patent—related U. Each week, we succinctly summarize the preceding week of Federal Circuit precedential patent opinions.

Akamai Techs., Inc. v. Limelight Networks, Inc. – Wikipedia

For more information and to contact Joe please visit his profile page at the Troutman Sanders website.

Turning to the facts of the specific case before it, the court reversed the JMOL and reinstated the jury verdict. Patients can freely choose to bring their devices to their physician’s office and have their data extracted locally there. The physician would not himself hand the folic acid to the patient or “physically place the folic acid into the patient’s mouth.

Patent Why do you want a Patent? The citations in this article are written in Bluebook style. Limelight NetworksF. Who are Inventors and Joint Inventors? For more information and to contact Bob please visit his profile page at the Troutman Sanders website.

Thus, neither party directly infringed the patent. We welcome any feedback you may provide. He regularly handles complex and high-profile domestic and international patent portfolios, intellectual property agreements and licensing, IP evaluations for collaborations, mergers, and acquisitions.


As the court noted, FDA regulations require that the product labeling for a proposed generic version of an existing drug, such as Altima, must instruct physicians to follow exactly the claimed regimen, since the generic drug must be distributed with identical labeling to that for the original drug. Although Hjorth does not mention it, this is precisely the kind of patent unsuccessfully asserted in the Supreme Court’s Mayo decision. This includes directing your own customers commit a portion of the infringement for you, even if you have not agreed to indemnify them legally.

Akamai v. Limelight: Defendant may directly infringe where steps performed by a third party

Limelight cannot be liable for inducing infringement that never came to pass. Patent and Trademark Office post-grant proceedings. Bob applies more than 30 years of experience to IP counseling and litigation. When Do You Have an Invention? We provide the pertinent facts, issues, and holdings. The court noted that this is copyright law’s “vicarious liability” rule as stated in Metro-Goldwyn-Mayer Studios Inc.

From Wikipedia, the free encyclopedia. EG August 21, 9: Although the parties present extensive arguments as to whether this constitutes the physician “administering” the folic acid, whether or not this satisfies the definition of “administer” is not relevant. In disputed Patent Office matters his work includes representing and counseling clients in interferences, reexaminations, reissues, post-grant proceedings, and in European Oppositions. He observes in the Patently-O blog that “a party could be liable for inducement where it induced another party who itself performed some of the steps and the remaining steps were attributable to the induced party even if performed by another [third party].

In the remand decision, the Federal Circuit expanded the scope of vicarious liability in such cases, holding that one actor could be held liable for the acts of another actor “when an alleged infringer conditions participation in an activity or receipt of a benefit upon performance of a step or steps of a patented method and establishes the manner or timing of that performance.


The evidence presented to the district court indisputably shows that Medtronic does not condition the use of, or receipt of a benefit from, the CareLink System on the performance of all of Medgraph’s method steps. This page was last edited on 12 Decemberat The en banc court found it unnecessary to consider direct infringement under 35 U.

Federal Circuit Review — Issue No. See also 21 CFR But the Federal Circuit then granted en banc review and reversed.

a,amai His practice encompasses litigation, including Hatch-Waxman litigation; licensing; counseling; due diligence; and patent and trademark prosecution. Retrieved from ” https: His work includes patent procurement, strategic planning and transactional advice, due diligence investigations, district court patent cases, and Federal Circuit appeals.

The en banc court characterized the problem as determining, when “more than one actor is involved in practicing the steps” of a method claim of a patent, whether the acts of one actor are attributable to the other actor such that second one is to be held “responsible for the infringement. It will be interesting to see whether the Royal Nine will accept another petition for cert in this case. After this case, it will be more difficult to avoid patent infringement by simply delegating some of the steps in the process to another party.

For example, a company may own a patent that covers a diagnostic method having steps that could be practiced by two entities, a physician and a laboratory.

Convertible Top Replacement Co.